CA2172512A1 - Interaction de recepteurs de cellules t et d'antigenes dans des maladies auto-immunes - Google Patents

Interaction de recepteurs de cellules t et d'antigenes dans des maladies auto-immunes

Info

Publication number
CA2172512A1
CA2172512A1 CA002172512A CA2172512A CA2172512A1 CA 2172512 A1 CA2172512 A1 CA 2172512A1 CA 002172512 A CA002172512 A CA 002172512A CA 2172512 A CA2172512 A CA 2172512A CA 2172512 A1 CA2172512 A1 CA 2172512A1
Authority
CA
Canada
Prior art keywords
seq
leu
type
amino acid
topology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002172512A
Other languages
English (en)
Inventor
Lawrence Steinman
Jorge Oksenberg
Claud Bernard
Scott Zamvil
Dennis J. Mitchell
Nathan Karin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2172512A1 publication Critical patent/CA2172512A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des procédés pour déterminer les relations qui existent entre les maladies dégénératives auto-immunes et les régions variables spécifiques des récepteurs de lymphocytes T, telles qu'elles sont associées à l'antigène leucocytaire humain hôte ou au lymphocyte T qui se combinent dans la lutte contre le les maladies néoprolifératives. En identifiant les récepteurs de lymphocytes T particuliers qui causent ou qui constituent la maladie chez les mammifères, diverses techniques prophylactiques et thérapeutiques peuvent être utilisées pour empêcher l'attaque des récepteurs de lymphocytes T sur les protéines ou les tissus natifs, afin d'accroître les défenses immunologiques. On peut en outre par diagnostic examiner des individus pour établir leur propension à développer une maladie auto-immune particulière ou pour déterminer la présence d'une telle maladie.
CA002172512A 1993-09-22 1994-09-22 Interaction de recepteurs de cellules t et d'antigenes dans des maladies auto-immunes Abandoned CA2172512A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12540793A 1993-09-22 1993-09-22
US08/125,407 1993-09-22

Publications (1)

Publication Number Publication Date
CA2172512A1 true CA2172512A1 (fr) 1995-03-30

Family

ID=22419571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002172512A Abandoned CA2172512A1 (fr) 1993-09-22 1994-09-22 Interaction de recepteurs de cellules t et d'antigenes dans des maladies auto-immunes

Country Status (5)

Country Link
EP (1) EP0720622A1 (fr)
JP (1) JPH09502981A (fr)
AU (1) AU695801B2 (fr)
CA (1) CA2172512A1 (fr)
WO (1) WO1995008572A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
CA2133749A1 (fr) * 1992-04-09 1993-10-28 Howard L. Weiner Suppression de la proliferation de lymphocytes t a l'aide de fragments peptidiques de la proteine de base de la myeline
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
AU721898B2 (en) * 1994-11-18 2000-07-20 Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A2 (fr) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Analogues peptidiques de proteine de base de myeline utile dans le traitement de la sclerose en plaques
DE19625191A1 (de) * 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
GR20000100282A (el) * 2000-08-17 2002-05-24 Αποστολοπουλου Βασω Πεπτιδικα αναλογα επιτοπων της βασικης πρωτεινης της μυελινης για τη θεραπεια της πειραματικης αυτοανοσης εγκεφαλομυελιτιδας καιτης σκληρυνσης κατα πλακας
EP1370582A1 (fr) * 2001-03-23 2003-12-17 John Matsoukas Analogues peptidiques d'epitopes de proteine de base de myeline intervenant dans le traitement de l'encephalomyelite auto-immune experimentale (eae) et de la sclerose en plaques
CN1723201A (zh) * 2003-01-10 2006-01-18 三菱制药株式会社 血脑屏障破坏的抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0587735T3 (da) * 1991-05-31 2000-09-11 Immune Response Corp Inc T-cellereceptorpeptider som terapeutiske midler til immunrelateret sygdom
WO1993012814A2 (fr) * 1991-12-24 1993-07-08 The Immune Response Corporation Vaccination et procedes contre des maladies resultant de reponses pathogenes de populations de lymphocytes t specifiques

Also Published As

Publication number Publication date
WO1995008572A1 (fr) 1995-03-30
EP0720622A1 (fr) 1996-07-10
JPH09502981A (ja) 1997-03-25
AU7840694A (en) 1995-04-10
AU695801B2 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
US5667967A (en) T-cell receptor varible transcripts as disease related markers
AU635202B2 (en) Anti-t-cell receptor determinants as autoimmune disease treatment
Zamvil et al. Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition.
US6090387A (en) Vaccination and methods against diseases resulting from pathogenic responses
CA2188182A1 (fr) Sequences receptrices de lymphocytes t conservees
AU695801B2 (en) Interaction of T-cell receptors and antigen in autoimmune disease
EP0722738A2 (fr) Vaccination et procédés contre des maladies issues de réponses pathogènes par des populations spécifiques de cellules T
CA2078549C (fr) Recepteur des lymphocytes de la sclerose en plaques
AU660606B2 (en) Diagnosis and treatment of diseases
KR20070097423A (ko) 흉선-특이성 단백질
Ogata et al. cDNA clone spanning the alpha-gamma subunit junction in the precursor of the murine fourth complement component (C4).
AU653527B2 (en) T-cell receptor variable transcripts as disease related markers
CA1327162C (fr) Methode de traitement prophylactique de personnes atteintes de maladies auto-immunes
US6039947A (en) Peptides derived from immunodominant epitopes of myelin basic protein
JP2001500013A (ja) ＨＴ▲下ｍ４▼、治療およびアッセイ方法、アゴニストおよびアンタゴニスト
Shirwan et al. Structure and diversity of rat T cell receptor alpha-chain genes.
JPH06507630A (ja) 哺乳類ｔ細胞の応答を調節する方法
CA2485874A1 (fr) Sequences cdr3 des recepteurs des lymphocytes t et procedes de detection associes
Chen et al. Oligoclonal expansion of T cell receptor V beta 2 and 3 cells in the livers of mice with graft-versus-host disease
Tjoa T-cell receptor diversity of various antigen-specific T cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead